Standardised incidence ratios (SIR) and 95% confidence intervals (CI) of oesophageal cancer and estimation of oesophageal adenocarcinoma in the study cohorts
| Oesophageal cancer | Estimation for oesophageal adenocarcinoma | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Obs OC | Exp OC | SIR (95% CI) | SIR ratio (95% CI) | Exp non-OAC | Exp* non-OAC | Est Obs OAC | Exp OAC | SIR (95% CI) | SIR ratio (95% CI) | |
| *Corrected. | ||||||||||
| Obs, observed; Exp, expected; OC, oesophageal cancer; OAC, adenocarcinoma. | ||||||||||
| All men and women (43 cancers) | ||||||||||
| Barrett’s | 13 | 1.0 | 13 (7–22.2) | 9.8 (4.3–21.6) | 0.65 | 0.87 | 12.13 | 0.31 | 39.1 (20.2–68.3) | 29.8 (9.6–106) |
| Oesophagitis | 8 | 2.8 | 2.9 (1.2–5.6) | 2.1 (0.8–5.3) | 1.95 | 2.6 | 5.4 | 0.9 | 6.0 (1.9–14) | 4.5 (1.0–19.6) |
| Reflux | 6 | 2.7 | 2.2 (0.8–4.8) | 1.7 (0.5–4.5) | 1.87 | 2.49 | 3.51 | 0.86 | 4.1 (1.1–10.5) | 3.1 (0.6–14.2) |
| Standard ref | 16 | 12.0 | 1.3 (0.8–2.2) | 1.00 | 8.16 | 10.88 | 5.12 | 3.84 | 1.3 (0.4–3.1) | 1.00 |
| Men (30 cancers) | ||||||||||
| Barrett’s | 9 | 0.6 | 15 (6.9–28.5) | 10.3 (3.8–26.5) | 0.4 | 0.59 | 8.41 | 0.25 | 33.6 (14.5–66.3) | 23.2 (6.6–89) |
| Oesophagitis | 5 | 1.9 | 2.6 (0.9–6.1) | 1.8 (0.5–5.5) | 1.16 | 1.7 | 3.3 | 0.71 | 4.6 (1–13.6) | 3.2 (0.5–16.3) |
| Reflux | 4 | 1.8 | 2.2 (0.6–5.7) | 1.5 (0.4–5) | 1.12 | 1.64 | 2.36 | 0.68 | 3.5 (0.4–12.5) | 2.4 (0.2–14.4) |
| Standard ref | 12 | 8.2 | 1.5 (0.8–2.6) | 1.00 | 5.07 | 7.45 | 4.55 | 3.1 | 1.5 (0.5–3.4) | 1.00 |
| Women (13 cancers) | ||||||||||
| Barrett’s | 4 | 0.3 | 13.3 (3.6–34.1) | 12.7 (2.4–68) | 0.25 | 0.26 | 3.74 | 0.06 | 62.3 (22–130.6) | 60.3 (5.9–2949) |
| Oesophagitis | 3 | 1.0 | 3 (0.6–8.8) | 2.9 (0.4–16.8) | 0.79 | 0.83 | 2.17 | 0.19 | 11.4 (1.4–41.3) | 10.9 (0.6–648) |
| Reflux | 2 | 0.9 | 2.2 (0.3–8) | 2.1 (0.2–14.7) | 0.75 | 0.78 | 1.22 | 0.18 | 6.8 (0.2–37.8) | 6.5 (0.08–511) |
| Standard ref | 4 | 3.8 | 1.1 (0.3–2.7) | 1.00 | 3.09 | 3.23 | 0.77 | 0.74 | 1.0 (0.03–5.8) | 1.00 |